Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1985 May;85(1):179–187. doi: 10.1111/j.1476-5381.1985.tb08845.x

The in vitro pharmacology of xamoterol (ICI 118,587).

E Malta, M A Mian, C Raper
PMCID: PMC1916765  PMID: 2862938

Abstract

The effect of xamoterol and (-)-isoprenaline have been compared for their activity at beta-adrenoceptor sites in a number of in vitro cardiac and smooth muscle preparations. Xamoterol produced weak positive chronotropic effects in guinea-pig, rat and cat atria (intrinsic activity less than 0.55, (-)-isoprenaline = 1). Positive inotropic effects were obtained in driven left atria of the cat but were absent in guinea-pig left atrial and right ventricular strip preparations. Agonistic effects were due to beta 1-adrenoceptor stimulation. Xamoterol was without beta-adrenoceptor-mediated inhibitory effects in guinea-pig ileal, tracheal and uterine preparations and in the rat vas deferens and oestrogen-primed uterus. Weak beta 2-adrenoceptor-mediated relaxation was obtained in progesterone-primed rat uteri. Xamoterol produced non-specific inhibitory effects in guinea-pig ileal and tracheal preparations. Xamoterol acted as a competitive antagonist at beta 1-(pA2 range = 7.4 to 7.8) and beta 2-adrenoceptors (pA2 range 5.2 to 6.2) and displaced [125I]-iodocyanopindolol from guinea-pig left atrial (pKD = 7.25) and uterine (pKD 5.24) membrane preparations. It is concluded that xamoterol displays a selective affinity for beta 1-adrenoceptors. Although its partial agonistic actions are more evident at beta 1-adrenoceptor sites, like prenalterol, xamoterol displays a degree of tissue rather than receptor-dependent selectivity.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARUNLAKSHANA O., SCHILD H. O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. doi: 10.1111/j.1476-5381.1959.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Apperley G. H., Drew G. M., Sullivan A. T. Prenalterol is an agonist at beta 2- as well as at beta 1-adrenoceptors. Eur J Pharmacol. 1982 Jul 30;81(4):659–663. doi: 10.1016/0014-2999(82)90356-9. [DOI] [PubMed] [Google Scholar]
  3. Barlow J. J., Main B. G., Snow H. M. Beta-adrenoceptor stimulant properties of amidoalkylamino-substituted 1-aryl-2-ethanols and 1-(aryloxy)-2-propanols. J Med Chem. 1981 Mar;24(3):315–322. doi: 10.1021/jm00135a015. [DOI] [PubMed] [Google Scholar]
  4. Benfey B. G., Varma D. R. Interactions of sympathomimetic drugs, propranolol and phentolamine, on atrial refractory period and contractility. Br J Pharmacol Chemother. 1967 Aug;30(3):603–611. doi: 10.1111/j.1476-5381.1967.tb02166.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cook N., Richardson A., Barnett D. B. Comparison of the beta 1 selective affinity of prenalterol and corwin demonstrated by radioligand binding. Eur J Pharmacol. 1984 Mar 2;98(3-4):407–412. doi: 10.1016/0014-2999(84)90289-9. [DOI] [PubMed] [Google Scholar]
  6. Iakovidis D., Malta E., McPherson G. A., Raper C. In vitro activity of RO363, a beta1-adrenoceptor selective agonist. Br J Pharmacol. 1980 Apr;68(4):677–685. doi: 10.1111/j.1476-5381.1980.tb10860.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Johansson L. H., Persson H. Beta 2-adrenoceptors in guinea-pig atria. J Pharm Pharmacol. 1983 Dec;35(12):804–807. doi: 10.1111/j.2042-7158.1983.tb02900.x. [DOI] [PubMed] [Google Scholar]
  8. Kenakin T. P., Beek D. Is prenalterol (H133/80) really a selective beta 1 adrenoceptor agonist? Tissue selectivity resulting from differences in stimulus-response relationships. J Pharmacol Exp Ther. 1980 May;213(2):406–413. [PubMed] [Google Scholar]
  9. Kenakin T. P. Theoretical and practical problems with the assessment of intrinsic efficacy of agonists: efficacy of reputed beta-1 selective adrenoceptor agonists for beta-2 adrenoceptors. J Pharmacol Exp Ther. 1982 Nov;223(2):416–423. [PubMed] [Google Scholar]
  10. Krstew E., Malta E., Raper C. Comparison of guinea pig uterine and rat vas deferens preparations for assessment of beta 2-adrenoceptor-mediated activity. J Pharmacol Methods. 1982 Dec;8(4):279–289. doi: 10.1016/0160-5402(82)90045-6. [DOI] [PubMed] [Google Scholar]
  11. Malta E., Raper C. Non-catechol phenylethanolamines: agonistic and antagonistic actions on beta-adrenoreceptors in isolated tissues from the guinea-pig. Clin Exp Pharmacol Physiol. 1974 May-Jun;1(3):259–268. doi: 10.1111/j.1440-1681.1974.tb00548.x. [DOI] [PubMed] [Google Scholar]
  12. Malta E., Raper C., Tawa P. E. Pre- and postjunctional effects of clonidine- and oxymetazoline-like compounds in guinea-pig ileal preparations. Br J Pharmacol. 1981 Jun;73(2):355–362. doi: 10.1111/j.1476-5381.1981.tb10429.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mattsson H., Andersson T., Carlsson E., Hedberg A., Lundgren B., Olsson T. beta 1-and beta 2-adrenoceptor stimulatory effects of prenalterol. Naunyn Schmiedebergs Arch Pharmacol. 1982 Dec;321(4):302–308. doi: 10.1007/BF00498518. [DOI] [PubMed] [Google Scholar]
  14. Mattsson H., Hedberg A., Carlsson E. Intrinsic sympathomimetic activity of the partial agonist prenalterol in relation to beta adrenoceptor interaction in various tissues, in vitro. J Pharmacol Exp Ther. 1983 Mar;224(3):654–661. [PubMed] [Google Scholar]
  15. McPherson G. A. A practical computer-based approach to the analysis of radioligand binding experiments. Comput Programs Biomed. 1983 Aug-Oct;17(1-2):107–113. doi: 10.1016/0010-468x(83)90031-4. [DOI] [PubMed] [Google Scholar]
  16. McPherson G. A., Malta E., Molenaar P., Raper C. The affinity and efficacy of the selective beta 1-adrenoceptor stimulant RO363 at beta 1- and beta 2-adrenoceptor sites. Br J Pharmacol. 1984 Aug;82(4):897–904. doi: 10.1111/j.1476-5381.1984.tb16488.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Mian M. A., Malta E., Raper C. An homogeneous population of beta 1-adrenoceptors subserves inhibitory responses in guinea-pig ileal preparations. J Pharm Pharmacol. 1984 Oct;36(10):698–699. doi: 10.1111/j.2042-7158.1984.tb04849.x. [DOI] [PubMed] [Google Scholar]
  18. Munson P. J., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980 Sep 1;107(1):220–239. doi: 10.1016/0003-2697(80)90515-1. [DOI] [PubMed] [Google Scholar]
  19. Mylecharane E. J., Raper C. Beta-receptor blocking and cardiodepressant actions of 2-nitrilophenoxypropanolamines. Eur J Pharmacol. 1971 Sep;16(1):14–20. doi: 10.1016/0014-2999(71)90051-3. [DOI] [PubMed] [Google Scholar]
  20. Nuttall A., Snow H. M. The cardiovascular effects of ICI 118,587: A beta 1-adrenoceptor partial agonist. Br J Pharmacol. 1982 Oct;77(2):381–388. doi: 10.1111/j.1476-5381.1982.tb09309.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. O'Donnell S. R., Wanstall J. C. Pharmacological approaches to the characterization of beta-adrenoreceptor populations in tissues. J Auton Pharmacol. 1981 Sep;1(4):305–312. doi: 10.1111/j.1474-8673.1981.tb00460.x. [DOI] [PubMed] [Google Scholar]
  22. Smith H. J., Halliday S. E., Briscoe M. G., Snow H. M. Facilitation of calcium blocking and membrane effects by intrinsic sympathomimetic activity. Cardiovasc Res. 1984 Jan;18(1):30–36. doi: 10.1093/cvr/18.1.30. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES